ERBB2 and breast cancer: Previous studies have shown that the pCR of breast cancer patients after neoadjuvant chemotherapy is about 1–68% [21–23], varying according to the cancer subtype: 1% for luminal A, 8% for luminal B, 38% for HER2-positive, and 23% for triple-negative [23].